LOIM
IBRX icon

Liberty One Investment Management’s ImmunityBio IBRX Stock Holding History

Liberty One Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-47,687
Closed -$239K – 189
2023
Q4 		$239K Buy
47,687
+109
+0.2% +$342 0.03% 118
2023
Q3 		$80.4K Sell
47,578
-3,009
-6% -$6.04K 0.01% 130
2023
Q2 		$141K Buy
50,587
+19,698
+64% +$55.7K 0.02% 130
2023
Q1 		$56.2K Buy
30,889
+810
+3% +$2.52K 0.01% 134
2022
Q4 		$153K Sell
30,079
-43
-0.1% -$236 0.02% 122
2022
Q3 		$150K Buy
30,122
+18,042
+149% +$82.2K 0.02% 122
2022
Q2 		$173K Sell
12,080
-16,984
-58% -$68.2K 0.03% 126
2022
Q1 		$163K Sell
29,064
-20,400
-41% -$125K 0.02% 132
2021
Q4 		$301K Buy
49,464
+37,504
+314% +$282K 0.05% 112
2021
Q3 		$116K Sell
11,960
-120
-1% -$1.32K 0.02% 137
2021
Q2 		$173K Buy
+12,080
New +$200K 0.03% 137

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Liberty One Investment Management's IBRX Position: Q1 2024 in Review

Liberty One Investment Management sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 47,687 shares — an estimated $239K sold.

Liberty One Investment Management first reported a position in IBRX in Q2 2021 and held it in 11 quarters. The position peaked at $301K in Q4 2021. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

  • Liberty One Investment Management reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
  • Liberty One Investment Management sold 47,687 ImmunityBio shares in Q1 2024, an estimated $239K.
  • Liberty One Investment Management first reported a position in ImmunityBio in Q2 2021 and held it in 11 quarters.
  • Liberty One Investment Management's ImmunityBio position peaked at $301K in Q4 2021.
  • 165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Liberty One Investment Management's 13F filing for Q1 2024, filed 30 Apr 2024.